Celcuity (CELC) Stock Price, News & Analysis

Company Overview

Celcuity, Inc. is a biotechnology company focused on advancing personalized medicine through functional diagnostics. Its technology is designed to analyze living tumor cells obtained from patient tissue and identify abnormal signaling activity that may influence how a cancer responds to specific therapies.

The company’s primary platform, CELsignia, uses proprietary assays to measure the activity of cellular signaling pathways in a patient’s tumor cells. Celcuity develops these tests for use in oncology drug development, patient selection, and potentially as companion diagnostics to help identify patients who are most likely to benefit from targeted treatments.

Celcuity works with biopharmaceutical companies and research organizations to evaluate drug-response biomarkers and support precision oncology programs. The company is based in Minnesota and was founded by Brian Sullivan, who serves as its chief executive officer. Its activities are centered on the development and commercialization of diagnostic technologies for cancer care and pharmaceutical research.

Key Stats

• Today's Range: $77.07 to $80.19
• 50-Day Range: $79.37 to $96.43
• 52-Week Range: $44.42 to $151.02
• Volume: 1.24 million shs
• Average Volume: 798,986 shs
• Market Capitalization: $3.88 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $154.75
• Consensus Rating: Moderate Buy

Celcuity Stock Analysis - MarketRank™

Celcuity scored higher than 56% of companies evaluated by MarketBeat, and ranked 412th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Celcuity has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Celcuity has a consensus price target of $154.75, representing about 95.0% upside from its current price of $79.37.

Amount of Analyst Coverage

Celcuity has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Celcuity are expected to grow in the coming year, from ($4.82) to ($2.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Celcuity is -18.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celcuity is -18.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celcuity has a P/B Ratio of 36.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.79% of the float of Celcuity has been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 12.48, which indicates bearish sentiment.

Change versus previous month

Short interest in Celcuity has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celcuity does not currently pay a dividend.

Dividend Growth

Celcuity does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.43

News Sentiment

Celcuity has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Celcuity this week, compared to 6 articles on an average week.

Search Interest

11 people have searched for CELC on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.

MarketBeat Follows

3 people have added Celcuity to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celcuity insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.33% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CELC
• CIK: 1603454
• Web: www.celcuity.com
• Phone: (763) 392-0767
• Fax: N/A
• Employees: 155
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Celcuity: $154.75
• High Price Target: $178.00
• Low Price Target: $110.00
• Potential Upside/Downside: +95.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$177.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -350.78%
• Return on Assets: -41.54%

Debt

• Debt-to-Equity Ratio: 6.04
• Current Ratio: 8.93
• Quick Ratio: 8.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.17 per share
• Price / Book: 36.58

Miscellaneous

• Outstanding Shares: 48,930,000
• Free Float: 42,409,000
• Market Cap: $3.88 billion
• Optionable: Optionable
• Beta: 0.19